ALPHA3 is enrolling patients with LBCL who are likely to relapse after first-line treatment. Such relapses can be not only aggressive but can occur quickly following completion of therapy.

The following is a summary of “Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With ...

Allogene Therapeutics recently released exciting results from the Phase 1 ALPHA/ALPHA2 trials of the Allogeneic CAR T 'Cemacabtagene Ansegedleucel/ALLO-501' in Relapsed/Refractory Large B-Cell ...

CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 ---- Advancing four clinical programs for ...

Based on its cash, cash equivalents and investments as of December 31, the company continues to expect its cash runway to fund operations into ...

This treatment is for adults with relapsed or refractory large B-cell lymphoma or LBCL, including diffuse large B-cell lymphoma or DLBCL and high-grade B-cell lymphoma or HGBL, after at least two ...

LBCL 291 course syllabus [PDF download 250 KB] This course is an integrated study of the nature of the visual arts from antiquity to the 20th century. Artistic expression is examined through ...

Its lead program, IMPT-314, is in Phase 1/2 clinical development for relapsed or refractory aggressive large B-cell lymphoma (LBCL) and its preclinical programs target solid tumor indications.

CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 -- -- Advancing four clinical programs for hematologic malignancies and autoimmune diseases -- --$249 ...

Presented positive initial data from Phase 1 multi-center clinical trial of IMPT-314 in patients with aggressive LBCL in the ...